Therapeutic potential of osimertinib in the treatment of lung cancer with HER2 aberrations

Lung cancer remains a leading cause of cancer-related mortality in both male and female worldwide. Non-small cell lung cancer (NSCLC) including adenocarcinoma, squamous cell carcinoma and large cell carcinoma constitutes the majority of lung cancer (~85%) cases. As a result of the technical advance and the availability of targeted drugs, systematic testing for major gene mutations has become standard of care for clinical decision-making